Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 9—September 2012
Dispatch

Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium

Liesbet Van Heirstraeten, Samuel Coenen, Christine Lammens, Niel Hens, Herman Goossens, and Surbhi Malhotra-KumarComments to Author 
Author affiliations: University of Antwerp, Antwerp, Belgium (L. Van Heirstraeten, S. Coenen, C. Lammens, N. Hens, H. Goossens, S. Malhotra-Kumar); and University of Hasselt, Hasselt, Belgium (N. Hens)

Main Article

Figure 2

Predominant geno-emm-types that accounted for >5% of macrolide-resistant S. pyogenes, Belgium, 1999–2009.

Figure 2. . Predominant geno-emm-types that accounted for >5% of macrolide-resistant Streptococcus pyogenes, Belgium, 1999–2009.

Main Article

Page created: August 17, 2012
Page updated: August 17, 2012
Page reviewed: August 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external